EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

View source ↗

Summary

EMA authorises Comirnaty (BioNTech) for COVID-19 virus infection as a vaccine based on mRNA technology.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Disease

Drugs mentioned

• Comirnaty (tozinameran)

Snippet

Status: Authorised. Therapeutic area: COVID-19 virus infection. MAH: BioNTech Manufacturing GmbH. Decision date: 26/05/2026